A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas
Latest Information Update: 27 Apr 2023
At a glance
- Drugs Adavosertib (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 22 Apr 2023 Status changed from active, no longer recruiting to completed.
- 04 Dec 2020 Planned primary completion date changed from 1 Nov 2020 to 21 May 2021.
- 06 Aug 2020 Planned primary completion date changed from 30 Jun 2020 to 1 Nov 2020.